The German Institute for Quality and Efficiency in Health Care (IQWiG) has now re-examined the added benefit of aclidinium bromide (trade names Eklira, Bretaris) under the Act on the Reform of the Market for Medicinal Products (AMNOG).
The drug has been approved since July 2012 and is used to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults. It was developed by Spain’s largest drugmaker Almirall (ALM: MC), which has since transferred the rights to its respiratory franchise to Anglo-Swedish drug major AstraZeneca (LSE: AZN; The Pharma Letter July 30, 2014).
In contrast to the first dossier assessment from 2012, the IQWiG now sees proof of considerable added benefit on the basis of newly submitted data. This only applies to one patient group, however, namely adults with COPD grade III and fewer than two exacerbations (flare-ups) per year. These patients have fewer flare-ups under aclidinium bromide.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze